News
Acadia Healthcare Acquires Four CTC Facilities in Georgia
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the recent acquisition of four comprehensive treatment centers (“CTC”) from Georgia-based Brand New Start Treatment Centers. The four
EQS-News: Burcon Reports Fiscal 2023 Second Quarter Results
IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today
EQS-News: Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth
Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay of pending litigation to provide additional time for the parties to finalize their litigation settlement
Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
QIAGEN übertrifft Ausblick für Q3 2022 mit einem Umsatzwachstum von 18% (CER) beim Nicht-COVID-Portfolio und hebt Ausblick für das Gesamtjahr 2022 an
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Ergebnisse für das dritte Quartal und die ersten neun Monate 2022 bekannt gegeben und die Prognose für das Gesamtjahr 2022
QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the third quarter of 2022 and first nine months of 2022, and increased the outlook for full-year 2022.
Net sales for
Xencor Reports Third Quarter 2022 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced topline
Poxel Announces Upcoming Participation at the Jefferies London Healthcare Conference
POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
EQS-News: Burcon NutraScience Corp.: Burcon Appoints Specialty Protein Executive Kip Underwood as Chief Executive Officer
Charles River Announces Cell Therapy Manufacturing Capacity Expansion, Reinforcing Commitment to CDMO Clients
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its cell therapy contract development and manufacturing (CDMO) facility in Memphis, Tenn. The expanded
Agilent Joins the How2Recycle Program
Agilent Technologies Inc. (NYSE: A) has become a member of How2Recycle®, a standardized labeling system owned by Delaware nonprofit Green Blue Institute, Inc. The program involves a coalition of
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study
Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
Transgene Reports Business Update And Q3 2022 Financial Position
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)
Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Chemed Corporation Declares Quarterly Dividend of 38 Cents
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 38-cents per share on the Company’s capital stock, payable on December 5, 2022
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today